Antisense and RNAi Therapeutics Market Size, Top Share

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Antisense and RNAi Therapeutics Market Size Analysis

Global Antisense and RNAi Therapeutics Market Introduction
By Technology
1. Introduction
  1. Technology By Value
2. RNA Interference
  1. By Value
3. siRNA
  1. By Value
4. miRNA
  1. By Value
5. Antisense RNA
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Cardiovascular Diseases (CVDs)
  1. By Value
4. Respiratory Disorders
  1. By Value
5. Renal Diseases
  1. By Value
6. Neurodegenerative Disorders
  1. By Value
7. Genetic Disorders
  1. By Value
8. Infectious Diseases
  1. By Value
9. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Subcutaneous Route
  1. By Value
4. Intrathecal Route
  1. By Value
5. Pulmonary Delivery
  1. By Value
6. Intraperitoneal Injection
  1. By Value
7. Others
  1. By Value

North America Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. RNA Interference
  1. By Value
3. siRNA
  1. By Value
4. miRNA
  1. By Value
5. Antisense RNA
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Cardiovascular Diseases (CVDs)
  1. By Value
4. Respiratory Disorders
  1. By Value
5. Renal Diseases
  1. By Value
6. Neurodegenerative Disorders
  1. By Value
7. Genetic Disorders
  1. By Value
8. Infectious Diseases
  1. By Value
9. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Subcutaneous Route
  1. By Value
4. Intrathecal Route
  1. By Value
5. Pulmonary Delivery
  1. By Value
6. Intraperitoneal Injection
  1. By Value
7. Others
  1. By Value
U.S.
1. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Interference
    1. By Value
  3. siRNA
    1. By Value
  4. miRNA
    1. By Value
  5. Antisense RNA
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Diseases (CVDs)
    1. By Value
  4. Respiratory Disorders
    1. By Value
  5. Renal Diseases
    1. By Value
  6. Neurodegenerative Disorders
    1. By Value
  7. Genetic Disorders
    1. By Value
  8. Infectious Diseases
    1. By Value
  9. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Subcutaneous Route
    1. By Value
  4. Intrathecal Route
    1. By Value
  5. Pulmonary Delivery
    1. By Value
  6. Intraperitoneal Injection
    1. By Value
  7. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. RNA Interference
  1. By Value
3. siRNA
  1. By Value
4. miRNA
  1. By Value
5. Antisense RNA
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Cardiovascular Diseases (CVDs)
  1. By Value
4. Respiratory Disorders
  1. By Value
5. Renal Diseases
  1. By Value
6. Neurodegenerative Disorders
  1. By Value
7. Genetic Disorders
  1. By Value
8. Infectious Diseases
  1. By Value
9. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Subcutaneous Route
  1. By Value
4. Intrathecal Route
  1. By Value
5. Pulmonary Delivery
  1. By Value
6. Intraperitoneal Injection
  1. By Value
7. Others
  1. By Value
U.K.
1. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Interference
    1. By Value
  3. siRNA
    1. By Value
  4. miRNA
    1. By Value
  5. Antisense RNA
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Diseases (CVDs)
    1. By Value
  4. Respiratory Disorders
    1. By Value
  5. Renal Diseases
    1. By Value
  6. Neurodegenerative Disorders
    1. By Value
  7. Genetic Disorders
    1. By Value
  8. Infectious Diseases
    1. By Value
  9. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Subcutaneous Route
    1. By Value
  4. Intrathecal Route
    1. By Value
  5. Pulmonary Delivery
    1. By Value
  6. Intraperitoneal Injection
    1. By Value
  7. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. RNA Interference
  1. By Value
3. siRNA
  1. By Value
4. miRNA
  1. By Value
5. Antisense RNA
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Cardiovascular Diseases (CVDs)
  1. By Value
4. Respiratory Disorders
  1. By Value
5. Renal Diseases
  1. By Value
6. Neurodegenerative Disorders
  1. By Value
7. Genetic Disorders
  1. By Value
8. Infectious Diseases
  1. By Value
9. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Subcutaneous Route
  1. By Value
4. Intrathecal Route
  1. By Value
5. Pulmonary Delivery
  1. By Value
6. Intraperitoneal Injection
  1. By Value
7. Others
  1. By Value
China
1. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Interference
    1. By Value
  3. siRNA
    1. By Value
  4. miRNA
    1. By Value
  5. Antisense RNA
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Diseases (CVDs)
    1. By Value
  4. Respiratory Disorders
    1. By Value
  5. Renal Diseases
    1. By Value
  6. Neurodegenerative Disorders
    1. By Value
  7. Genetic Disorders
    1. By Value
  8. Infectious Diseases
    1. By Value
  9. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Subcutaneous Route
    1. By Value
  4. Intrathecal Route
    1. By Value
  5. Pulmonary Delivery
    1. By Value
  6. Intraperitoneal Injection
    1. By Value
  7. Others
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. RNA Interference
  1. By Value
3. siRNA
  1. By Value
4. miRNA
  1. By Value
5. Antisense RNA
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Cardiovascular Diseases (CVDs)
  1. By Value
4. Respiratory Disorders
  1. By Value
5. Renal Diseases
  1. By Value
6. Neurodegenerative Disorders
  1. By Value
7. Genetic Disorders
  1. By Value
8. Infectious Diseases
  1. By Value
9. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Subcutaneous Route
  1. By Value
4. Intrathecal Route
  1. By Value
5. Pulmonary Delivery
  1. By Value
6. Intraperitoneal Injection
  1. By Value
7. Others
  1. By Value
UAE
1. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Interference
    1. By Value
  3. siRNA
    1. By Value
  4. miRNA
    1. By Value
  5. Antisense RNA
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Diseases (CVDs)
    1. By Value
  4. Respiratory Disorders
    1. By Value
  5. Renal Diseases
    1. By Value
  6. Neurodegenerative Disorders
    1. By Value
  7. Genetic Disorders
    1. By Value
  8. Infectious Diseases
    1. By Value
  9. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Subcutaneous Route
    1. By Value
  4. Intrathecal Route
    1. By Value
  5. Pulmonary Delivery
    1. By Value
  6. Intraperitoneal Injection
    1. By Value
  7. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. RNA Interference
  1. By Value
3. siRNA
  1. By Value
4. miRNA
  1. By Value
5. Antisense RNA
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Cardiovascular Diseases (CVDs)
  1. By Value
4. Respiratory Disorders
  1. By Value
5. Renal Diseases
  1. By Value
6. Neurodegenerative Disorders
  1. By Value
7. Genetic Disorders
  1. By Value
8. Infectious Diseases
  1. By Value
9. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Subcutaneous Route
  1. By Value
4. Intrathecal Route
  1. By Value
5. Pulmonary Delivery
  1. By Value
6. Intraperitoneal Injection
  1. By Value
7. Others
  1. By Value
Brazil
1. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Interference
    1. By Value
  3. siRNA
    1. By Value
  4. miRNA
    1. By Value
  5. Antisense RNA
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Diseases (CVDs)
    1. By Value
  4. Respiratory Disorders
    1. By Value
  5. Renal Diseases
    1. By Value
  6. Neurodegenerative Disorders
    1. By Value
  7. Genetic Disorders
    1. By Value
  8. Infectious Diseases
    1. By Value
  9. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Subcutaneous Route
    1. By Value
  4. Intrathecal Route
    1. By Value
  5. Pulmonary Delivery
    1. By Value
  6. Intraperitoneal Injection
    1. By Value
  7. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Antisense and RNAi Therapeutics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

GSK plc
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Olix Pharmaceuticals, Inc.
Sanofi
Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma Inc.
Silence Therapeutics
Ionis Pharmaceuticals, Inc
Sarepta Therapeutics
Percheron Therapeutics Limited

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment